Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

44 results about "Stem cell biology" patented technology

Compositions and methods for modular soft tissue repair

InactiveUS20100098739A1Superior in vivo engraftmentSuperior in tissue integrationBiocideMammal material medical ingredientsSerum free mediaTissue repair
Adipose tissue-derived stromal cells induced to form multicellular aggregates can be formed reliably and consistently, they can be maintained for prolonged periods in adherent or suspension culture, and they are able to survive, grow, and / or differentiate in serum-free media conditions. The present invention provides compositions and methods for the use of such aggregates in tissue repair. This culture platform provides a controlled and defined system in which to study and standardize adult stem cell biology, and begets an instinctive “modular” approach to the predictable replacement and regeneration of adipose tissue.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND

Preparation of human umbilical cord mesenchymal stem cells wound surface smearing agent and storage application method

The invention discloses a method for separating, purifying and culturing human umbilical mesenchymal stem cells and a method for preparing, storing and quickly preparing and applying a wound surface painting reagent of the human umbilical mesenchymal stem cells. The method comprises: firstly, separating, purifying and culturing the human umbilical mesenchymal stem cells; secondly, preparing a methyl cellulose composite culture medium; thirdly, preparing the wound surface painting reagent of the human umbilical mesenchymal stem cells; and fourthly, detecting the biological properties of the human umbilical mesenchymal stem cells. The method takes methyl cellulose as a substrate, mixes the human umbilical mesenchymal stem cells into the methyl cellulose, and generates the wound surface painting reagent of the human umbilical mesenchymal stem cells, and the wound surface painting reagent can be uniformly coated on the wound surface of the skin to form a coating. The invention performs preclinical researches such as animal toxicity test, pyrogen test and hypersensitive test, constructs a cryopreservation resuscitation method for human umbilical mesenchymal stem cells and a stem cell bank, and prepares for large-scale production and preparation of the wound surface painting reagent of the human umbilical mesenchymal stem cells and application of the wound surface painting reagent of the human umbilical mesenchymal stem cells.
Owner:戴育成

Midbrain dopamine (DA) neurons for engraftment

The present invention relates to the field of stem cell biology, in particular the lineage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions. The midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons made using the methods of the present invention are further contemplated for various uses including, but not limited to, use in in vitro drug discovery assays, neurology research, and as a therapeutic to reverse disease of, or damage to, a lack of dopamine neurons in a patient. Further, compositions and methods are provided for differentiating midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons from human pluripotent stem cells for use in disease modeling, in particular Parkinson's disease. Additionally, authentic DA neurons are enriched for markers, such as CD142, and A9 type neuronal cells.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Method for differentiating human pluripotent stem cells into natural killer cells and application

The invention relates to the field of stem cell biology, specifically to a method for differentiating human pluripotent stem cells into natural killer cells and an application. The invention disclosesa pluripotent stem cell-derived natural killer cell. The pluripotent stem cell-derived natural killer cell expresses CD56, Nkp30, Nkp44 and Nkp46, and also expresses markers CD16 and CD94 of a maturenatural killer cell. The invention also discloses a method for preparing the natural killer cell. The method comprises the following steps: S1, formation of an embryoid body; S2, differentiation of the embryoid body into hematopoietic progenitor cells; S3, differentiation of the hematopoietic progenitor cells into NK cells; and S4, maturation and expansion of the NK cells. With the differentiation method provided by the invention, the pluripotent stem cells can be rapidly, efficiently, simply and conveniently induced to be differentiated into the natural killer cells with low cost on the basis of a culture medium with definite components and an optimized cell factor combination.
Owner:安徽中盛溯源生物科技有限公司

Natural killer cell differentiated from human pluripotent stem cells as well as preparation method and application thereof

The invention relates to the field of stem cell biology, and discloses a preparation method of natural killer cells differentiated from human pluripotent stem cells. The preparation method comprises the steps of S1, forming an embryoid body; S2, performing directional permanent hematopoiesis differentiation on the embryoid body to obtain hematopoietic precursor cells; and S3, differentiating the hematopoietic precursor cells to obtain natural killer cells. The invention also discloses application of the natural killer cell prepared by the method as a pharmaceutical composition for preventing and/or treating tumors by cells. According to the method, efficient and stable differentiation of the NK cells is achieved, EB adherent differentiation is achieved in the induced differentiation period, TGFB inhibitor treatment is prolonged, 10% or above of CD34+CD45+permanent hematopoietic HPCs can be obtained through rapid induction. The method has the advantages of being efficient, stable, low in cost and suitable for large-scale cell preparation production; and the method is easy and convenient to operate, the NK cells obtained through differentiation have typical NK cell surface marking molecules, the anti-tumor function of the NK cells is superior to that of the NK cells derived from umbilical cord blood, and great scientific research and clinical application potentials are achieved.
Owner:深圳市济因生物科技有限公司

Method for inducing cardiac differentiation of stem cells by utilizing small molecule compounds

The invention discloses a method for inducing cardiac differentiation of stem cells by utilizing small molecule compounds, relating to the fields of stem cell biology and regenerative medicines. The small molecule compounds refer to a type of carbamate compounds (I) or medicinal salts, hydrates, solvates and isomers thereof. The method comprises the following steps: adding the small molecule compounds into a differential medium to directly act on tested cells, continuously using the small molecule compounds according to the form and growth states of the tested cells and the identification conditions until the expression level of corresponding target genes in the tested cells is increased, and differentiating the tested cells into cardiomyocyte-like cells, wherein the stem cells comprise embryonic stem cells, induced pluripotent stem cells and mesenchymal stem cells. The experiment proves that after the inducers are added into the cell differentiation medium, the myocardial cell differentiation proportion of the stem cells is obviously improved. The differential medium containing a type of carbamate compounds or medicinal salts, hydrates, solvates and isomers thereof can be used for inducing the stem cells to be differentiated into myocardial cells.
Owner:XIAMEN UNIV

Cardiomyocyte maturation

This disclosure generally concerns the fields of cell biology and molecular biology. In particular the invention concerns the field of stem cell biology and maturation of stem cell-derived cardiomyocytes. Disclosed is a method for improving the maturity of stem-cell derived cardiomyocytes, in particular of the ventricular type, as can be witnessed by, for example, an improved upstroke velocity of the stem-cell derived cardiomyocytes.
Owner:NCARDIA BV

Kidney epithelial cell and preparation method and application thereof

The invention relates to the field of stem cell biology, in particular to a kidney epithelial cell and a preparation method and application thereof. The first disclosed kidney epithelial cell expresses CDH1<+> and PODXL<+>, and at least expresses one of CDH2<+> and LTL<+>. The second disclosed preparation method of the kidney epithelial cell includes the following steps that pluripotent stem cellsare differentiated into posterior streak cells; the posterior streak cells are differentiated into posterior intermediate mesoderms; the posterior intermediate mesoderms are differentiated into kidney progenitor cells; the kidney progenitor cells are differentiated into kidney tubular aggregated precursors; the kidney tubular aggregated precursors are differentiated into kidney vesicles; and thekidney vesicles are differentiated into kidney epithelial cells. The provided preparation method has high differentiation efficiency and stable differentiation effect, and is applied to a variety of hPSC cell lines; and the differentiated nephron progenitor cells can meet the requirements of kidney disease model building, kidney drug toxicity testing, kidney disease related drug screening and other scientific research experiment.
Owner:安徽中盛溯源生物科技有限公司

Method for inducing adipose tissue-derived stem cells to differentiate into testicular interstitial-like cells by single transcription factor

The invention relates to a method for inducing adipose tissue-derived stem cells to differentiate into testicular interstitial-like cells by a single transcription factor, and belongs to the fields of stem cell biology and regenerative medicine. According to the method, chemically modified mRNA of a transcription factor NR5A1 is synthesized in vitro, exosomes extracted from autologous urine of a patient are used as a delivery carrier to form an exosome-modNR5A1 compound, and then the exosome-modNR5A1 compound and ADMSCs derived from autologous tissue of the patient are co-cultured to induce the ADMSCs to be differentiated into Leydig-like cells with a testosterone secretion function. According to the method disclosed by the invention, the Leydig-like cells with the testosterone secretion function can be quickly and efficiently obtained, meanwhile, the cells can effectively react to the stimulation of luteinizing hormone, and the cells have a gene expression profile related to the androgen synthesis of mature Leydig cells. The Leydig cell obtained by the invention has a good application prospect in the aspect of treatment of male hypogonadism.
Owner:THE FIRST AFFILIATED HOSPITAL OF HENAN UNIV OF SCI & TECH

Preparation of human umbilical cord mesenchymal stem cells wound surface smearing agent and storage application method

The invention discloses a method for separating, purifying and culturing human umbilical mesenchymal stem cells and a method for preparing, storing and quickly preparing and applying a wound surface painting reagent of the human umbilical mesenchymal stem cells. The method comprises: firstly, separating, purifying and culturing the human umbilical mesenchymal stem cells; secondly, preparing a methyl cellulose composite culture medium; thirdly, preparing the wound surface painting reagent of the human umbilical mesenchymal stem cells; and fourthly, detecting the biological properties of the human umbilical mesenchymal stem cells. The method takes methyl cellulose as a substrate, mixes the human umbilical mesenchymal stem cells into the methyl cellulose, and generates the wound surface painting reagent of the human umbilical mesenchymal stem cells, and the wound surface painting reagent can be uniformly coated on the wound surface of the skin to form a coating. The invention performs preclinical researches such as animal toxicity test, pyrogen test and hypersensitive test, constructs a cryopreservation resuscitation method for human umbilical mesenchymal stem cells and a stem cell bank, and prepares for large-scale production and preparation of the wound surface painting reagent of the human umbilical mesenchymal stem cells and application of the wound surface painting reagent of the human umbilical mesenchymal stem cells.
Owner:戴育成

Detection method for in-vitro inhibition of Th1 and Th17 by mesenchymal stem cells

The invention relates to the technical field of stem cell biology, in particular to a detection method for in-vitro Th1 and Th17 inhibition of mesenchymal stem cells. The method comprises the following steps: 1, co-culturing mesenchymal stem cells and peripheral blood mononuclear cells; 2, carrying out fixed membrane rupture dyeing and detection. According to the detection method provided by the invention, lymphocyte proliferation and differentiation are promoted through co-culture of mesenchymal stem cells and peripheral mononuclear cells, so that the expression of the inhibition effect of the mesenchymal stem cells is promoted, and the inhibition effect is improved. According to the method, the PBMC cells obtained through co-culture are stimulated and blocked, so that factor secretion is promoted, meanwhile, inhibition and factor blocking are added for detection, so that expression of Th1 and Th17 in the PBMC cells is further promoted, expression of Th1 and Th17 obtained through detection is improved, and the inhibition effect is further improved.
Owner:华夏源(上海)生命科技有限公司

Midbrain dopamine (DA) neurons for engraftment

The present invention relates to the field of stem cell biology, in particular the lineage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and / or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions. The midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons made using the methods of the present invention are further contemplated for various uses including, but not limited to, use in in vitro drug discovery assays, neurology research, and as a therapeutic to reverse disease of, or damage to, a lack of dopamine neurons in a patient. Further, compositions and methods are provided for differentiating midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons from human pluripotent stem cells for use in disease modeling, in particular Parkinson's disease. Additionally, authentic DA neurons are enriched for markers, such as CD142, and A9 type neuronal cells.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products